FCCC LOGO Faculty Publications
Engstrom PF , Ryan LM , Falkson G , Haller DG
Phase-Ii Study of Aminothiadiazole in Advanced Squamous-Cell Carcinoma of the Esophagus
American Journal of Clinical Oncology-Cancer Clinical Trials. 1991 Feb;14(1) :33-35
PMID: ISI:A1991EV47900007   
Back to previous list
Abstract
Twenty-three patients with advanced inoperable squamous cell carcinoma of the esophagus were treated with aminothiadiazole (A-TD) 125 mg/m2 weekly plus allopurinol daily in a phase II cooperative group trial. No patients responded to treatment; 17 patients progressed, three showed stable disease, and three were unevaluable. There were no life-threatening hematologic or metabolic toxicities. The median survival from study entry was 5 months. A-TD is not active in advanced squamous cell carcinoma of the esophagus.
Notes
EV479 AMER J CLIN ONCOL-CANC CLIN T